Clinical trials: Type 1 Hypersensitivity
Hereditary Angioedema (HAE)
A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt
Hereditary angioedema (HAE) is a rare condition. It causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals. This swelling happens because of a temporary leak in blood vessels.
- Trial name
- EXPLORHAE (NCT07218393)
- Testing
- No intervention
- Where
- 7 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Takeda
Coronary Disease, Myocardial Infarction
Chronical Illness-related Limitations of the Ability to Cope with Rising Temperatures: an Observational Study, 2nd Wave
The CLIMATE-II Observational Study examines to what extent chronically ill patients experience adverse health effects because of heat and whether the patients' specific health behavior, somatosensory amplification, risk and…
- Conditions
- Coronary Disease, Myocardial Infarction, Heart Failure, Arrhythmias, Cardiac
- Trial name
- CLIMATE-II (NCT06407154)
- Where
- Germany
- Volunteers
- 578 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Angioedema
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be…
- Trial name
- NCT00125541
- Testing
- C1 inhibitor concentrate (C1-esteraseremmer-N)
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Prothya Biosolutions
Type I Hypersensitivity
Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
Safety and tolerability of different dose combinations of MPL and grass pollen allergen and to identify the highest combinations of MPL and grass pollen allergen which is safe.
- Trial name
- NCT00241410
- Testing
- OralvacB2MPL
- Where
- Germany
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Diagnosis and Physiopathology of Insulin Allergy
Insulin allergy (IA) is still observed even with recombinant human insulin and insulin analogs. Obviously, the usual attitude facing an allergy, i. e.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypersensitivity, Immediate Hypersensitivity
- Trial name
- Allerdiab (NCT01407640)
- Testing
- Allergy tests
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2
Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)
The purpose of this study is to determine the key factors influencing insulin sensitivity in type 1 diabetes (T1DM) and maturity onset diabetes of the young, type 2 (MODY2).
- Conditions
- Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
- Trial name
- NCT02971202
- Testing
- Hyperinsulinemic, euglycemic clamp, 20% dextrose
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Allergic Rhinitis, Effects of Immunotherapy
Distinct Response of CD4+CD25+Foxp3+ and IL-10-secreting Type I T Regulatory Cells to Cluster Specific Immunotherapy in Allergic Rhinitis Children
While allergen specific immunotherapy (SIT) is highly effective for allergic diseases in children, the underlying immunological mechanisms are unclear. Regulatory T (Treg) cells may be crucial in induction of tolerance.
- Trial name
- NCT01291381
- Testing
- Dermatophagoides pteronyssinus, Pharmacotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Tongren Hospital
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Type 1 Diabetes (T1D), Metabolic Diseases
METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
The study is a randomized, double-blind, parallel-group clinical trial to examine the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with Type 1 Diabetes (T1D) (n=30 per…
- Conditions
- Type 1 Diabetes (T1D), Metabolic Diseases, Glucose Metabolism Disorders, Endocrine System Diseases
- Trial name
- MetMod-T1D (NCT07699380)
- Testing
- AMX0035
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 60 people
- Sponsor
- University of Washington
Obesity in Diabetes, Obesity/Therapy
Semaglutide Treatment in Type 1 Diabetes
The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic…
- Conditions
- Obesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM), Insulin Sensitivity/Resistance
- Trial name
- OBES1TY (NCT06909006)
- Testing
- Semaglutide 2.4mg
- Where
- Denmark
- Volunteers
- 122 people
- Sponsor
- Nordsjaellands Hospital
Atopic Dermatitis, Type 1 Hypersensitivity
Allergic Disease Onset Prevention Study
This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1…
- Trial name
- adored (NCT05003804)
- Testing
- STMC-103H
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- Siolta Therapeutics, Inc.